Plain-English translation of NCT06752577 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new approach using bone marrow-derived mesenchymal stem cells (MSCs) — special healing cells from bone marrow — to help protect kidney function in people with chronic kidney disease. The treatment is delivered through infusions into your bloodstream and directly to your kidneys. Researchers want to make sure this treatment is safe and well-tolerated before studying whether it actually slows kidney damage.
Chronic kidney disease often gets worse over time, even with current medications, and there are limited options to slow that decline — especially for people whose kidney transplants are failing. This trial exists to explore whether this new stem cell treatment might offer hope by helping kidneys work better and last longer.
You likely qualify if…
You likely don't qualify if…
You would receive infusions of stem cells either through a vein in your arm, or through both a vein and a catheter placed directly into your kidney arteries. After the infusion, you would have follow-up appointments to check for any side effects and monitor how well the treatment works. Depending on your response, you may be eligible to receive additional doses, and the research team will track your kidney function and overall health over time.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States